Molecular biology of lung cancer: clinical implications.

[1]  F. Wang,et al.  Octamer 4 Small Interfering RNA Results in Cancer Stem Cell-Like Cell Apoptosis , 2012 .

[2]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[3]  R. Rosell,et al.  Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. , 2011, Lung cancer.

[4]  Leah E. Mechanic,et al.  Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer , 2011, Oncogene.

[5]  J Downward,et al.  An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis , 2011, Oncogene.

[6]  X. Chen,et al.  Identification of ten serum microRNAs from a genome‐wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis , 2011, International journal of cancer.

[7]  J. Shay,et al.  Targeting telomerase-expressing cancer cells , 2011, Journal of cellular and molecular medicine.

[8]  W. Pao,et al.  How genetically engineered mouse tumor models provide insights into human cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yi Zhu,et al.  Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer , 2011, Chinese journal of cancer.

[10]  A. Sood,et al.  MicroRNA therapeutics: principles, expectations, and challenges , 2011, Chinese journal of cancer.

[11]  S. Leng,et al.  EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. , 2011, Cancer research.

[12]  T. Itoh,et al.  Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo. , 2011, Cancer research.

[13]  Wei Zhang,et al.  Genetic and epigenetic changes in lung carcinoma and their clinical implications , 2011, Modern Pathology.

[14]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[15]  F. Cui,et al.  CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. , 2011, Oncology reports.

[16]  Zhaoli Chen,et al.  DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer , 2011, Cancer biology & therapy.

[17]  Vidar Skaug,et al.  The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non–Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts , 2011, Clinical Cancer Research.

[18]  D. Gudbjartsson,et al.  Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk. , 2011, Cancer research.

[19]  Derek Y. Chiang,et al.  Suppression of Lung Adenocarcinoma Progression by Nkx2-1 , 2011, Nature.

[20]  S. Wacholder,et al.  Assessment of Human Papillomavirus in Lung Tumor Tissue , 2011, Journal of the National Cancer Institute.

[21]  K. Fong,et al.  Genomic medicine in non‐small cell lung cancer: Paving the path to personalized care , 2011, Respirology.

[22]  J. Minna,et al.  Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy , 2011, Molecular Cancer Therapeutics.

[23]  Alan Ashworth,et al.  Searching for synthetic lethality in cancer. , 2011, Current opinion in genetics & development.

[24]  C. Sautès-Fridman,et al.  Tumor microenvironment is multifaceted , 2011, Cancer and Metastasis Reviews.

[25]  T. Dønnem,et al.  Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization , 2011, Journal of Translational Medicine.

[26]  H. Osada,et al.  let‐7 and miR‐17‐92: Small‐sized major players in lung cancer development , 2011, Cancer science.

[27]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[28]  S. Chiou,et al.  Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. , 2010, Cancer research.

[29]  Feng Jiang,et al.  Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers , 2010, International journal of cancer.

[30]  John D. Minna,et al.  Nuclear Receptor Expression Defines a Set of Prognostic Biomarkers for Lung Cancer , 2010, PLoS medicine.

[31]  S. Ramalingam.  Histone Deacetylase, Proteasome, and Heat Shock Protein Inhibitors for the Treatment of Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  P. Jänne,et al.  Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. , 2010, Cancer research.

[33]  S. Dubinett,et al.  Poly(ADP-Ribose) Polymerase Inhibitors , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Laura A. Sullivan,et al.  Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. , 2010, Cancer research.

[35]  J. Yokota,et al.  Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. , 2010, Lung cancer.

[36]  W. Hahn,et al.  Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. , 2010, The Journal of clinical investigation.

[37]  Alan Ashworth,et al.  Synthetic lethal approaches to breast cancer therapy , 2010, Nature Reviews Clinical Oncology.

[38]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[39]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[40]  A. Gazdar.  Should we continue to use the term non-small-cell lung cancer? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  W. Park,et al.  Global analysis of CpG methylation reveals epigenetic control of the radiosensitivity in lung cancer cell lines , 2010, Oncogene.

[42]  L. Chirieac,et al.  Sox2 Protein Expression is an Independent Poor Prognostic Indicator in Stage I Lung Adenocarcinoma , 2010, The American journal of surgical pathology.

[43]  I. Yoshino,et al.  Aberrant methylation in non-small cell lung cancer , 2010, Surgery Today.

[44]  P. Wei,et al.  Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design , 2010, Molecular Cancer Therapeutics.

[45]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[46]  J. Coon,et al.  PTEN, RASSF1 and DAPK site‐specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients , 2010, International journal of cancer.

[47]  Z. Herceg,et al.  Aberrant DNA methylation links cancer susceptibility locus 15q25.1 to apoptotic regulation and lung cancer. , 2010, Cancer research.

[48]  Marshall W. Anderson,et al.  A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. , 2010, Cancer research.

[49]  Robert A. Weinberg,et al.  Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model , 2010, Nature Biotechnology.

[50]  John D. Minna,et al.  Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung , 2010, PloS one.

[51]  A. Pertsemlidis,et al.  microRNAs and lung cancer: tumors and 22-mers , 2010, Cancer and Metastasis Reviews.

[52]  C. Sima,et al.  Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer , 2010, Cancer.

[53]  S. Zöchbauer-Müller,et al.  Lung cancer: From single-gene methylation to methylome profiling , 2010, Cancer and Metastasis Reviews.

[54]  John D. Minna,et al.  Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy , 2010, Cancer and Metastasis Reviews.

[55]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[56]  J. Hornick,et al.  Sox2 Expression in Pulmonary Non-small Cell and Neuroendocrine Carcinomas , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[57]  Laura A. Sullivan,et al.  Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway , 2010, Experimental biology and medicine.

[58]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[59]  Raoul Tibes,et al.  Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. , 2009, The New England journal of medicine.

[60]  John D. Minna,et al.  Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer , 2010 .

[61]  K. Okudela,et al.  Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. , 2009, Lung cancer.

[62]  M. Varella‐Garcia,et al.  ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[64]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.

[65]  Bernat Gel,et al.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. , 2009, Carcinogenesis.

[66]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[67]  Marshall W. Anderson,et al.  Haplotype and cell proliferation analyses of candidate lung cancer susceptibility genes on chromosome 15q24-25.1. , 2009, Cancer research.

[68]  D. Carvajal,et al.  Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. , 2009, Cancer research.

[69]  Y. Maehara,et al.  Clinicopathological significance of Sip1-associated epithelial mesenchymal transition in non-small cell lung cancer progression. , 2009, Anticancer research.

[70]  W. Hsu,et al.  Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer , 2009, Thorax.

[71]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[72]  William Pao,et al.  Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications , 2009, Clinical Cancer Research.

[73]  Alexander Pertsemlidis,et al.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.

[74]  G. Viglietto,et al.  The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[75]  M. Spitz,et al.  Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. , 2009, Cancer research.

[76]  N. Girard,et al.  Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers , 2009, Clinical Cancer Research.

[77]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[78]  G. Pirozzi,et al.  Human CD34+/CD90+ ASCs Are Capable of Growing as Sphere Clusters, Producing High Levels of VEGF and Forming Capillaries , 2009, PloS one.

[79]  John D. Minna,et al.  miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1 , 2009, Molecular Cancer Research.

[80]  Ru-Fang Yeh,et al.  Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. , 2009, Cancer research.

[81]  A. Schetter,et al.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.

[82]  D. Beer,et al.  MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. , 2009, Cancer research.

[83]  F. Esposito,et al.  TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. , 2009, Cancer letters.

[84]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[85]  T. Rauch,et al.  DNA methylation patterns in lung carcinomas. , 2009, Seminars in cancer biology.

[86]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[87]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[88]  Gideon Rechavi,et al.  Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Marshall W. Anderson,et al.  Fine Mapping of Chromosome 6q23-25 Region in Familial Lung Cancer Families Reveals RGS17 as a Likely Candidate Gene , 2009, Clinical Cancer Research.

[90]  J. Bankson,et al.  The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects , 2009, Molecular Cancer Therapeutics.

[91]  E. Scott,et al.  Aldehyde dehydrogenase activity as a functional marker for lung cancer. , 2009, Chemico-biological interactions.

[92]  C. Klinge,et al.  Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells , 2009, Nucleic acids research.

[93]  Akhilesh Pandey,et al.  Identification of miR‐21 targets in breast cancer cells using a quantitative proteomic approach , 2009, Proteomics.

[94]  Feng Jiang,et al.  Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.

[95]  G. Scagliotti,et al.  Nonsmall cell lung cancer in never smokers , 2009, Current opinion in oncology.

[96]  M. Stratton,et al.  LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition , 2009, British Journal of Cancer.

[97]  A. Sorkin,et al.  RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. , 2009, Molecular biology of the cell.

[98]  M. Meyerson,et al.  HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy , 2009, Proceedings of the National Academy of Sciences.

[99]  H. Drabkin,et al.  Semaphorins and their receptors in lung cancer. , 2009, Cancer letters.

[100]  Giovanni Vanni Frajese,et al.  The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice , 2008, PloS one.

[101]  Yu Liang.  An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer , 2008, BMC Medical Genomics.

[102]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[103]  L. Bierut,et al.  Nicotinic Receptor Gene Variants Influence Susceptibility to Heavy Smoking , 2008, Cancer Epidemiology Biomarkers & Prevention.

[104]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[105]  Maarit Tiirikainen,et al.  Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. , 2008, Cancer research.

[106]  N. Probst-Hensch,et al.  Prognostic Significance of Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition Protein Expression in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[107]  M. Spitz,et al.  The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. , 2008, Journal of the National Cancer Institute.

[108]  L. Siu,et al.  First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting , 2008, Journal of hematology & oncology.

[109]  J. Minna,et al.  Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. , 2008, Cancer research.

[110]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[111]  Vassilis Georgoulias,et al.  Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. , 2008, Clinical chemistry.

[112]  F. Siannis,et al.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.

[113]  Y. Yatabe,et al.  Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[114]  J. Nevins,et al.  Toward the individualization of lung cancer therapy , 2008, Cancer.

[115]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[116]  Jinsong Liu,et al.  Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. , 2008, Cancer research.

[117]  G. Nuovo,et al.  MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. , 2008, Biochemical and biophysical research communications.

[118]  M. Nikiforova,et al.  The Histopathology of BRAF-V600E–mutated Lung Adenocarcinoma , 2008, The American journal of surgical pathology.

[119]  W. Lam,et al.  PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.

[120]  Tatiana Foroud,et al.  Variants in nicotinic receptors and risk for nicotine dependence. , 2008, The American journal of psychiatry.

[121]  Anna E. Lokshin,et al.  Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties , 2008, PloS one.

[122]  Yang Xie,et al.  Predicting the future for people with lung cancer , 2008, Nature Medicine.

[123]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[124]  Yuh-Lih Chang,et al.  Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells , 2008, PloS one.

[125]  Christoph Plass,et al.  Lung cancer epigenetics and genetics , 2008, International journal of cancer.

[126]  M. Meyerson,et al.  Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.

[127]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[128]  Megan E. Piper,et al.  A Candidate Gene Approach Identifies the CHRNA5-A3-B4 Region as a Risk Factor for Age-Dependent Nicotine Addiction , 2008, PLoS genetics.

[129]  A. A. Abd El-Aty,et al.  Characterization of a stem cell population in lung cancer A549 cells. , 2008, Biochemical and biophysical research communications.

[130]  C. Croce,et al.  MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer , 2008, Oncogene.

[131]  I Petersen,et al.  Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer , 2008, Oncogene.

[132]  Manuel Benito,et al.  Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. , 2008, Lung cancer.

[133]  F. Hirsch,et al.  EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[134]  A. Adjei,et al.  K-ras as a Target for Lung Cancer Therapy , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[135]  Antony V. Cox,et al.  Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing , 2008, Nature Genetics.

[136]  M. Ladanyi,et al.  Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[137]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[138]  G. Mills,et al.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 , 2008, Nature Genetics.

[139]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[140]  Mauro Biffoni,et al.  The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. , 2008, Cancer research.

[141]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[142]  J. Roth,et al.  Tumor suppressor FUS1 signaling pathway. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[143]  M. Gaub,et al.  MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[144]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[145]  F. Slack,et al.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.

[146]  Phillip A Sharp,et al.  Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.

[147]  A. Sakurada,et al.  siRNA Targeting against EGFR, a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma , 2008, Pathobiology.

[148]  Hubert Vesselle,et al.  DNA Methylation in Tumor and Matched Normal Tissues from Non-Small Cell Lung Cancer Patients , 2008, Cancer Epidemiology Biomarkers & Prevention.

[149]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[150]  Xihong Lin,et al.  VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  Hong Wu,et al.  Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. , 2008, Cancer research.

[152]  M. Dohadwala,et al.  Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[153]  Lang Li,et al.  Association of polymorphisms of angiogenesis genes with breast cancer , 2008, Breast Cancer Research and Treatment.

[154]  B. Eren,et al.  MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas. , 2008, Annals of the Academy of Medicine, Singapore.

[155]  Xueyan Zhong,et al.  High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer , 2008, Proceedings of the National Academy of Sciences.

[156]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[157]  Diane D. Liu,et al.  Loss and Reduction of Fus1 Protein Expression is a Frequent Phenomenon in the Pathogenesis of Lung Cancer , 2008, Clinical Cancer Research.

[158]  Dong Sun Kim,et al.  Aberrant methylation of E‐cadherin and H‐cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features , 2007, Cancer.

[159]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[160]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[161]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[162]  Imran Babar,et al.  MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. , 2007, Cancer research.

[163]  R. Kurzrock,et al.  Interleukin‐6 and its receptor in cancer , 2007, Cancer.

[164]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[165]  Jude Kendall,et al.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.

[166]  M. Lauth,et al.  Non-Canonical Activation of GLI Transcription Factors: Implications for Targeted Anti-Cancer Therapy , 2007, Cell cycle.

[167]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[168]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[169]  J. Minna,et al.  Prevalence and specificity of LKB1 genetic alterations in lung cancers , 2007, Oncogene.

[170]  W. Pao,et al.  Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors , 2007, PloS one.

[171]  D. Neil Hayes,et al.  LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.

[172]  F. Slack,et al.  The let-7 microRNA represses cell proliferation pathways in human cells. , 2007, Cancer research.

[173]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[174]  J. Park,et al.  Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. , 2007, Lung cancer.

[175]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[176]  Y. Yatabe,et al.  Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. , 2007, Cancer research.

[177]  Y. Tomizawa,et al.  Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. , 2007, International journal of oncology.

[178]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[179]  Levi A Garraway,et al.  Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. , 2007, Cancer research.

[180]  Stephen Lam,et al.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. , 2007, Cancer research.

[181]  Anindya Dutta,et al.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. , 2007, Genes & development.

[182]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[183]  M. Bittner,et al.  Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. , 2007, Lung cancer.

[184]  Shuomin Zhu,et al.  miR-21-mediated tumor growth , 2007, Oncogene.

[185]  K. Robertson,et al.  Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer , 2007, Oncogene.

[186]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[187]  David P. Bartel,et al.  Supporting Online Material Materials and Methods Fig. S1 Tables S1 and S2 References Database S1 Disrupting the Pairing between Let-7 and Hmga2 Enhances Oncogenic Transformation , 2022 .

[188]  G. Dakubo,et al.  Clinical implications and utility of field cancerization , 2007, Cancer Cell International.

[189]  Sandya Liyanarachchi,et al.  Aberrant DNA Methylation of OLIG1, a Novel Prognostic Factor in Non-Small Cell Lung Cancer , 2007, PLoS medicine.

[190]  C. Shih,et al.  Identification of uPAR-positive Chemoresistant Cells in Small Cell Lung Cancer , 2007, PloS one.

[191]  E. Dmitrovsky,et al.  Frequent requirement of hedgehog signaling in non-small cell lung carcinoma , 2007, Oncogene.

[192]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[193]  B. Telfer,et al.  Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit , 2007, Molecular Cancer Therapeutics.

[194]  J. Minna,et al.  Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. , 2007, Cancer research.

[195]  W. Cai,et al.  High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. , 2007, Cancer letters.

[196]  M. Spitz,et al.  Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[197]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[198]  Lee L. Rubin,et al.  Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.

[199]  W. Gerald,et al.  A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies , 2006, PLoS medicine.

[200]  Yeul-Hong Kim,et al.  Comparative Genomic Hybridization Array Analysis and Real-Time PCR Reveals Genomic Copy Number Alteration for Lung Adenocarcinomas , 2006, Lung.

[201]  H. Sasaki,et al.  PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.

[202]  William Pao,et al.  Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors , 2006, Clinical Cancer Research.

[203]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[204]  M. Tsuboi,et al.  Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.

[205]  L. Heasley,et al.  Antitumorigenic Effect of Wnt 7a and Fzd 9 in Non-small Cell Lung Cancer Cells Is Mediated through ERK-5-dependent Activation of Peroxisome Proliferator-activated Receptor γ* , 2006, Journal of Biological Chemistry.

[206]  A. Villemain,et al.  The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. , 2006, Cancer research.

[207]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[208]  W. Sellers,et al.  Lineage dependency and lineage-survival oncogenes in human cancer , 2006, Nature Reviews Cancer.

[209]  N. Riobo,et al.  Hedgehog Signal Transduction: Signal Integration and Cross Talk in Development and Cancer , 2006, Cell cycle.

[210]  C. Swanton,et al.  Her2-Targeted Therapies in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[211]  H. Sasaki,et al.  Uncommon V599E BRAF mutations in Japanese patients with lung cancer. , 2006, The Journal of surgical research.

[212]  P. Jänne,et al.  The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.

[213]  H. Varmus,et al.  Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.

[214]  H. Koong,et al.  Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[215]  M. Meyerson,et al.  Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[216]  R. Cameron,et al.  Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. , 2006, Cancer research.

[217]  D. N. Watkins,et al.  Developmental signalling pathways in lung cancer , 2006, Respirology.

[218]  Y. Shim,et al.  Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. , 2006, Cancer research.

[219]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[220]  Raghu Kalluri,et al.  The epithelial–mesenchymal transition: new insights in signaling, development, and disease , 2006, The Journal of cell biology.

[221]  S. Lam,et al.  High resolution analysis of non‐small cell lung cancer cell lines by whole genome tiling path array CGH , 2006, International journal of cancer.

[222]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[223]  Wei Jiang,et al.  High-throughput DNA methylation profiling using universal bead arrays. , 2006, Genome research.

[224]  D. Sugarbaker,et al.  Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. , 2006, The Annals of thoracic surgery.

[225]  Mariette Schrier,et al.  A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors , 2006, Cell.

[226]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[227]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[228]  J. Minna,et al.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.

[229]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[230]  I. Wistuba,et al.  Lung cancer preneoplasia. , 2006, Annual review of pathology.

[231]  P. Tamboli,et al.  Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma , 2006, Cancer.

[232]  A. Gazdar,et al.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.

[233]  G. Cavet,et al.  Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.

[234]  N. Carter,et al.  Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non–Small Cell Lung Cancers , 2005, Clinical Cancer Research.

[235]  J. Minna,et al.  Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer , 2005, Genes, chromosomes & cancer.

[236]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[237]  Y. Yatabe,et al.  A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. , 2005, Cancer research.

[238]  E. Brown,et al.  Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.

[239]  J. Gills,et al.  Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. , 2005, Cancer research.

[240]  Takayuki Fukui,et al.  Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer , 2005, Oncogene.

[241]  J. Dick,et al.  Cancer stem cells: lessons from leukemia. , 2005, Trends in cell biology.

[242]  S. Hirohashi,et al.  Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features , 2005, Clinical Cancer Research.

[243]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[244]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[245]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[246]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[247]  G. Ito,et al.  Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. , 2005, Cancer letters.

[248]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[249]  L. Chin,et al.  High-resolution genomic profiles of human lung cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[250]  M. Meyerson,et al.  Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. , 2005, Cancer research.

[251]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[252]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[253]  Patricia L. Harris,et al.  Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[254]  N. Normanno,et al.  The ErbB receptors and their ligands in cancer: an overview. , 2005, Current drug targets.

[255]  F. Latif,et al.  Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. , 2005, Cancer research.

[256]  E. Smit,et al.  Molecular Pathology of Non-Small-Cell Lung Cancer , 2005, Respiration.

[257]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[258]  Wayne Tam,et al.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[259]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[260]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[261]  Suk Woo Nam,et al.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.

[262]  S. Knuutila,et al.  CDK4 is a probable target gene in a novel amplicon at 12q13.3–q14.1 in lung cancer , 2005, Genes, chromosomes & cancer.

[263]  A. Dudek,et al.  Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival , 2005, Cancer investigation.

[264]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[265]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[266]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[267]  J. Pollack,et al.  Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins , 2004, Cancer Research.

[268]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[269]  Li Mao,et al.  Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[270]  G. Watkins,et al.  The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. , 2004, International journal of molecular medicine.

[271]  K. Politi,et al.  Notch in mammary gland development and breast cancer. , 2004, Seminars in cancer biology.

[272]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[273]  Diane D. Liu,et al.  Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[274]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[275]  Marshall W. Anderson,et al.  A major lung cancer susceptibility locus maps to chromosome 6q23-25. , 2004, American journal of human genetics.

[276]  F. Jiang,et al.  Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. , 2004, Neoplasia.

[277]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[278]  K. Uematsu,et al.  Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells , 2004, Oncogene.

[279]  G. Rubanyi,et al.  Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors , 2004, BMC Cancer.

[280]  H. Kato,et al.  Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication. , 2004, Oncology reports.

[281]  G. Bepler,et al.  Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. , 2004, Chest.

[282]  Kimi Yamakoshi,et al.  The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. , 2004, The journal of medical investigation : JMI.

[283]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[284]  S. Toyooka,et al.  The relationship between aberrant methylation and survival in non-small-cell lung cancers , 2004, British Journal of Cancer.

[285]  Biao He,et al.  Wnt Inhibitory Factor-1 Is Silenced by Promoter Hypermethylation in Human Lung Cancer , 2004, Cancer Research.

[286]  G. Celik,et al.  The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. , 2004, Respiratory medicine.

[287]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[288]  Y. Shim,et al.  Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[289]  J. Minna,et al.  Different Roles for Caveolin-1 in the Development of Non-Small Cell Lung Cancer versus Small Cell Lung Cancer , 2004, Cancer Research.

[290]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[291]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[292]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[293]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[294]  J. Carretero,et al.  Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene , 2004, Oncogene.

[295]  Hiroyuki Tagawa,et al.  Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. , 2004, Cancer research.

[296]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[297]  Masahide Takahashi,et al.  p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma , 2004, Cancer.

[298]  R. Dziadziuszko,et al.  MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). , 2004, Lung cancer.

[299]  G. Neufeld,et al.  Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis , 2004, Cancer Research.

[300]  Arndt Borkhardt,et al.  High expression of precursor microRNA‐155/BIC RNA in children with Burkitt lymphoma , 2004, Genes, chromosomes & cancer.

[301]  C. Harris,et al.  Tobacco Carcinogen-Induced Cellular Transformation Increases Activation of the Phosphatidylinositol 3′-Kinase/Akt Pathway in Vitro and in Vivo , 2004, Cancer Research.

[302]  Biao He,et al.  Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression , 2003, Oncogene.

[303]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[304]  S. Anttila,et al.  Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer , 2003, International journal of cancer.

[305]  Christian Pilarsky,et al.  WIF1, a component of the Wnt pathway, is down‐regulated in prostate, breast, lung, and bladder cancer , 2003, The Journal of pathology.

[306]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[307]  B. Osborne,et al.  Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents , 2003, Oncogene.

[308]  David E. Misek,et al.  Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas , 2003, Oncogene.

[309]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[310]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[311]  Y. Shim,et al.  Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. , 2003, Cancer research.

[312]  C. Croce,et al.  Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. , 2003, Cancer research.

[313]  W. Koh,et al.  Survival among Chinese women with lung cancer in Singapore: a comparison by stage, histology and smoking status. , 2003, Lung cancer.

[314]  Y. Nishiwaki,et al.  Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. , 2003, Lung cancer.

[315]  T. Dang,et al.  Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice , 2003, Oncogene.

[316]  Stephen B. Baylin,et al.  Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer , 2003, Nature.

[317]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[318]  S. Turner,et al.  Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro , 2003, Molecular Cancer.

[319]  M. Meyerson,et al.  Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.

[320]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[321]  T. Hirano,et al.  Molecular basis of the cell specificity of cytokine action. , 2002, Biochimica et biophysica acta.

[322]  J. Testa,et al.  Chromosomal imbalances in human lung cancer , 2002, Oncogene.

[323]  R. Salgia,et al.  Activated c‐Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer , 2002, Journal of cellular and molecular medicine.

[324]  J. Minna,et al.  Aberrant DNA methylation in lung cancer: biological and clinical implications. , 2002, The oncologist.

[325]  Arvind Virmani,et al.  Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. , 2002, Cancer research.

[326]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[327]  W. Hahn,et al.  Immortalization and transformation of primary human airway epithelial cells by gene transfer , 2002, Oncogene.

[328]  David Sidransky,et al.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.

[329]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[330]  J. Minna,et al.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[331]  Ajay N. Jain,et al.  Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. , 2002, Cancer research.

[332]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[333]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[334]  A. Potti,et al.  Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. , 2002, Lung cancer.

[335]  Li Mao,et al.  Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[336]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[337]  R. Vonderheide.  Telomerase as a universal tumor-associated antigen for cancer immunotherapy , 2002, Oncogene.

[338]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[339]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[340]  J. Minna,et al.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. , 2001, Cancer research.

[341]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[342]  J. Minna,et al.  Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[343]  J. Minna,et al.  DNA methylation profiles of lung tumors. , 2001, Molecular cancer therapeutics.

[344]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[345]  S. Linn,et al.  Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene , 2001, Oncogene.

[346]  David Sidransky,et al.  Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival , 2001, Oncogene.

[347]  F. Oesch,et al.  c‐erbB‐2 Expression in small‐cell lung cancer is associated with poor prognosis , 2001, International journal of cancer.

[348]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[349]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[350]  J. Minna,et al.  5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. , 2001, Cancer research.

[351]  John K. Wiencke,et al.  p16INK4a and Histology-specific Methylation of CpG Islands by Exposure to Tobacco Smoke in Non-Small Cell Lung Cancer , 2001 .

[352]  J. Minna,et al.  Molecular genetics of small cell lung carcinoma. , 2001, Seminars in oncology.

[353]  J. Herman,et al.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. , 2001, Human molecular genetics.

[354]  C. Harris,et al.  Genetic polymorphisms in DNA repair genes and risk of lung cancer. , 2001, Carcinogenesis.

[355]  E. Mark,et al.  Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer , 2001, Oncogene.

[356]  R. Herrmann,et al.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[357]  M. Tsao,et al.  Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. , 2001, Cancer genetics and cytogenetics.

[358]  S. Piantadosi,et al.  Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. , 2001, Cancer research.

[359]  M. Tockman,et al.  Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[360]  J. Minna,et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.

[361]  R. Dillman,et al.  Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. , 2000, Seminars in oncology.

[362]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[363]  J. Roth,et al.  Gene replacement strategies for treating non-small cell lung cancer. , 2000, Seminars in radiation oncology.

[364]  T. Mitsudomi,et al.  Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[365]  F. Khuri,et al.  Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[366]  J. Minna,et al.  Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. , 2000, Cancer research.

[367]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[368]  T. Mitsudomi,et al.  Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. , 2000, The Annals of thoracic surgery.

[369]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[370]  J. Minna,et al.  Molecular changes in the bronchial epithelium of patients with small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[371]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[372]  P. Slootweg,et al.  Gain-of-function mutations in the tumor suppressor gene p53. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[373]  B. Kupelnick,et al.  Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. , 2000, Cancer letters.

[374]  J. Herman,et al.  CpG methylation is maintained in human cancer cells lacking DNMT1 , 2000, Nature.

[375]  S. Lam,et al.  High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. , 2000, Cancer research.

[376]  C. Der,et al.  Understanding Ras: 'it ain't over 'til it's over'. , 2000, Trends in cell biology.

[377]  T. Liloglou,et al.  Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker for malignant lung disease. , 2000, Lung cancer.

[378]  K. O'Byrne,et al.  Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer , 2000, British Journal of Cancer.

[379]  E. Brambilla,et al.  Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. , 2000, The American journal of pathology.

[380]  D. Harpole,et al.  Molecular biologic substaging of stage I lung cancer according to gender and histology. , 2000, The Annals of thoracic surgery.

[381]  J. Minna,et al.  Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features , 2000, British Journal of Cancer.

[382]  L. Norton,et al.  Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[383]  J. Minna,et al.  Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. , 2000, Cancer research.

[384]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[385]  J. Luketich,et al.  Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. , 2000, Journal of the National Cancer Institute.

[386]  J. Minna,et al.  Molecular pathogenesis of lung cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[387]  W. Prime,et al.  Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[388]  A. Hamburger,et al.  ErbB‐2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells , 1999, International journal of cancer.

[389]  S. Larson,et al.  Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[390]  E. Brambilla,et al.  Alterations of expression of Rb, p16INK4A and cyclin D1 in non‐small cell lung carcinoma and their clinical significance , 1999, The Journal of pathology.

[391]  D. E. Henson,et al.  Molecular Pathology of Early Cancer , 1999 .

[392]  J. Minna,et al.  Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. , 1999, Cancer research.

[393]  O. Miettinen,et al.  Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.

[394]  D. Spandidos,et al.  Microsatellite DNA instability in COPD. , 1999, Chest.

[395]  G. Thomas,et al.  Fine deletion mapping of chromosome 8p in non‐small‐cell lung carcinoma , 1999, International journal of cancer.

[396]  C. Harris,et al.  Mutational analysis of p73 and p53 in human cancer cell lines , 1999, Oncogene.

[397]  W. Hahn,et al.  The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.

[398]  J. Minna,et al.  Refined mapping of two regions of loss of heterozygosity on chromosome band 11q23 in lung cancer , 1999, Genes, chromosomes & cancer.

[399]  J. Yokota,et al.  Activation of RB tumor suppressor protein and growth suppression of small cell lung carcinoma cells by reintroduction of p16INK4A gene. , 1999, International journal of oncology.

[400]  W. Smythe,et al.  Cadherin and catenin expression in normal human bronchial epithelium and non-small cell lung cancer. , 1999, Lung cancer.

[401]  W. Prime,et al.  Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. , 1999, Cancer research.

[402]  J. Minna,et al.  Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. , 1999, Cancer research.

[403]  J. Minna,et al.  Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. , 1999, Cancer research.

[404]  M. Higashiyama,et al.  A novel molecular staging protocol for non-small cell lung cancer , 1999, Oncogene.

[405]  J. Minna,et al.  Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[406]  G. Dekan,et al.  The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[407]  W. Lee,et al.  RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[408]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[409]  Y. Ishikawa,et al.  Abnormal FHIT transcripts found in both lung cancer and normal lung tissue , 1999, Genes, chromosomes & cancer.

[410]  Jose M. Silva,et al.  TP53 gene mutations in plasma DNA of cancer patients , 1999, Genes, chromosomes & cancer.

[411]  M. Rooney,et al.  Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[412]  T. Hideshima,et al.  p53 mutations predict non-small cell lung carcinoma response to radiotherapy. , 1999, Cancer letters.

[413]  J. Minna,et al.  Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.

[414]  W P Bennett,et al.  Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer , 1999, The Journal of pathology.

[415]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[416]  R. Perng,et al.  Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[417]  P. Dayer,et al.  Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. , 1998, Pharmacogenetics.

[418]  L. Marchand,et al.  Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. , 1998, Cancer research.

[419]  Y. Yatabe,et al.  Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. , 1998, Journal of the National Cancer Institute.

[420]  J. Minna,et al.  Alterations of the PPP2R1B gene in human lung and colon cancer. , 1998, Science.

[421]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[422]  R. Brezinschek,et al.  Mutation analysis of the PTEN/MMAC1 gene in lung cancer , 1998, Oncogene.

[423]  E. Brambilla,et al.  The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. , 1998, Cancer research.

[424]  J. Minna,et al.  Progress in understanding the molecular pathogenesis of human lung cancer. , 1998, Biochimica et biophysica acta.

[425]  W. Hong,et al.  Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. , 1998, Journal of the National Cancer Institute.

[426]  E. Brambilla,et al.  p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[427]  W. Richards,et al.  Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[428]  C. Harris,et al.  Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. , 1998, British Journal of Cancer.

[429]  L. Liotta,et al.  Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. , 1998, Cancer research.

[430]  B. Dutrillaux,et al.  Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours , 1998, Oncogene.

[431]  L. Liotta,et al.  p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[432]  G. Tucker,et al.  Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. , 1998, Pharmacogenetics.

[433]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[434]  S. Satoh,et al.  Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[435]  Feng Li,et al.  Mass screening for lung cancer with mobile spiral computed tomography scanner , 1998, The Lancet.

[436]  J. Minna,et al.  Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types , 1998, Genes, chromosomes & cancer.

[437]  P. Zimmerman,et al.  KRAS codon 12 mutations in Australian non-small cell lung cancer. , 1998, Australian and New Zealand Journal of Medicine.

[438]  S. Nomoto,et al.  Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. , 1998, Cancer research.

[439]  J. V. van Noord,et al.  Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. , 1998, American journal of respiratory and critical care medicine.

[440]  F. Kaye,et al.  Protein expression and functional analysis of the FHIT gene in human tumor cells. , 1998, Journal of the National Cancer Institute.

[441]  H. Naiki,et al.  Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. , 1998, Cancer research.

[442]  R. Salgia,et al.  Molecular abnormalities in lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[443]  M. Higashiyama,et al.  Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[444]  J. Yokota,et al.  Identification of CpG islands hypermethylated in human lung cancer by the arbitrarily primed-PCR method , 1998, Human Genetics.

[445]  Y. Yatabe,et al.  p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. , 1998, Cancer research.

[446]  A. Giordano,et al.  p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. , 1998, American journal of respiratory cell and molecular biology.

[447]  V. Gouyer,et al.  Mechanisms of p16INK4A inactivation in non small-cell lung cancers , 1998, Oncogene.

[448]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[449]  L. D. Barnes,et al.  Replacement of Fhit in cancer cells suppresses tumorigenicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[450]  C. Bingle,et al.  Thyroid transcription factor-1. , 1997, The international journal of biochemistry & cell biology.

[451]  T. Zhukov,et al.  Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[452]  E. Dmitrovsky,et al.  High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. , 1997, Journal of the National Cancer Institute.

[453]  D. Warburton,et al.  Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. , 1997, American journal of physiology. Lung cellular and molecular physiology.

[454]  Y. Miller,et al.  Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. , 1997, The Journal of clinical investigation.

[455]  J. Siegfried,et al.  Prognostic value of specific KRAS mutations in lung adenocarcinomas. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[456]  Mark A. Stephenson,et al.  Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival , 1997, Cancer.

[457]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[458]  J. Siegfried,et al.  Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells. Association with prolonged tobacco exposure and responsiveness to bombesin-like peptides. , 1997, American journal of respiratory and critical care medicine.

[459]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[460]  K. Yasumoto,et al.  Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma , 1997, Cancer.

[461]  J. Samet,et al.  Molecular damage in the bronchial epithelium of current and former smokers. , 1997, Journal of the National Cancer Institute.

[462]  J. Mulshine,et al.  Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. , 1997, Chest.

[463]  J. Jen,et al.  Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[464]  R. Rosell,et al.  Reduced survival in patients with stage‐I non‐small‐cell lung cancer associated with DNA‐replication errors , 1997, International journal of cancer.

[465]  J S Lee,et al.  Clonal genetic alterations in the lungs of current and former smokers. , 1997, Journal of the National Cancer Institute.

[466]  C. Angeletti,et al.  Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.

[467]  S. Petersen,et al.  Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. , 1997, Cancer research.

[468]  I. Wistuba,et al.  Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. , 1997, Cancer research.

[469]  G. Giaccone,et al.  FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. , 1997, Cancer research.

[470]  G. Giaccone,et al.  Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[471]  A. Marchetti,et al.  Association between cigarette smoking and FHIT gene alterations in lung cancer. , 1997, Cancer research.

[472]  S. Ishiguro,et al.  MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. , 1997, British Journal of Cancer.

[473]  D. Bell,et al.  Advances in the analysis of chromosome alterations in human lung carcinomas. , 1997, Cancer genetics and cytogenetics.

[474]  F. Hirahara,et al.  Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. , 1997, Human pathology.

[475]  C. Angeletti,et al.  Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. , 1997, British Journal of Cancer.

[476]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[477]  W. Benedict,et al.  Altered retinoblastoma protein expression in nonsmall cell lung cancer , 1997, Cancer.

[478]  M. Volm,et al.  Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. , 1997, European journal of cancer.

[479]  K. Kerr,et al.  THE PATTERN OF K‐rasMUTATION IN PULMONARY ADENOCARCINOMA DEFINES A NEW PATHWAY OF TUMOUR DEVELOPMENT IN THE HUMAN LUNG , 1997, The Journal of pathology.

[480]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[481]  D. Romberger,et al.  Bombesin-like peptides and airway repair: a recapitulation of lung development? , 1997, American journal of respiratory cell and molecular biology.

[482]  A. El‐Naggar,et al.  Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. , 1997, The American journal of pathology.

[483]  M. Volm,et al.  Prognostic value of vascular endothelial growth factor and its receptor Flt‐1 in squamous cell lung cancer , 1997, International journal of cancer.

[484]  A. Schally,et al.  Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[485]  A. Marchetti,et al.  Alterations of P16 (MTS1) in node‐positive non‐small cell lung carcinomas , 1997, The Journal of pathology.

[486]  L. Weissfeld,et al.  Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. , 1997, Cancer research.

[487]  G. Bepler,et al.  Delineation of the centromeric and telomeric chromosome segment 11p15.5 lung cancer suppressor regions LOH11A and LOH11B , 1997, Genes, chromosomes & cancer.

[488]  M. Higashiyama,et al.  bcl‐2 oncoprotein in surgically resected nonsmall cell lung cancer: Possibly favorable prognostic factor in association with low incidence of distant metastasis , 1997, Journal of surgical oncology.

[489]  H. Dosaka-akita,et al.  Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. , 1996, Cancer research.

[490]  P. Zimmerman,et al.  MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer. , 1996, British Journal of Cancer.

[491]  E. Brambilla,et al.  Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. , 1996, The American journal of pathology.

[492]  R. Ball,et al.  IMMUNOREACTIVITY FOR HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND ITS RECEPTOR, met, IN HUMAN LUNG CARCINOMAS AND MALIGNANT MESOTHELIOMAS , 1996, The Journal of pathology.

[493]  P. Comoglio,et al.  Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. , 1996, British Journal of Cancer.

[494]  B. Karlan,et al.  DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. , 1996, Oncogene.

[495]  M. Mabry,et al.  Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung cancer. , 1996, Oncogene.

[496]  H. Kato,et al.  A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. , 1996, European journal of cancer.

[497]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[498]  T. Yamamoto,et al.  Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma. , 1996, Japanese journal of clinical oncology.

[499]  A. Kurt,et al.  Microsatellite alterations in plasma DNA of small cell lung cancer patients , 1996, Nature Medicine.

[500]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[501]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[502]  H. Kreipe,et al.  Expression of bcl-2--protein in small cell lung cancer. , 1996, Lung cancer.

[503]  A. Chella,et al.  Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA‐N2): Impact of adjuvant therapies in a subset of patients at high risk of recurrence , 1996, Cancer.

[504]  D. Niewoehner,et al.  Rb and p16INK4a expression in resected non-small cell lung tumors. , 1996, Cancer research.

[505]  J. Testa,et al.  Detection of aneuploidy in interphase nuclei from non-small cell lung carcinomas by fluorescence in situ hybridization using chromosome-specific repetitive DNA probes. , 1996, Cancer genetics and cytogenetics.

[506]  J. Yokota,et al.  Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[507]  C. Rose,et al.  Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. , 1996, British Journal of Cancer.

[508]  S. Hirohashi,et al.  Deletion mapping of chromosome 2 in human lung carcinoma , 1996, Genes, chromosomes & cancer.

[509]  U. Pastorino,et al.  Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. , 1996, Cancer research.

[510]  J. Battey,et al.  Insulin-like Growth Factor Expression in Human Cancer Cell Lines (*) , 1996, The Journal of Biological Chemistry.

[511]  R. Hruban,et al.  K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. , 1996, Cancer research.

[512]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[513]  M. Volm,et al.  Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. , 1996, British Journal of Cancer.

[514]  J. Minna,et al.  Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. , 1996, Cancer research.

[515]  D. Ward,et al.  Karyotyping human chromosomes by combinatorial multi-fluor FISH , 1996, Nature Genetics.

[516]  S. Elledge,et al.  Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. , 1996, Oncogene.

[517]  A. Marchetti,et al.  p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. , 1996, Oncogene.

[518]  A. Okamoto,et al.  Intragenic mutations of the p16INK4, p15INK4B and p18 genes in primary non‐small‐cell lung cancers , 1996 .

[519]  S. Jiang,et al.  Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. , 1996, The American journal of pathology.

[520]  R. Ueda,et al.  Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[521]  W. Ryder,et al.  Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. , 1996, British Journal of Cancer.

[522]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[523]  A. Gazdar,et al.  Extensive areas of aneuploidy are present in the respiratory epithelium of lung cancer patients. , 1996, British Journal of Cancer.

[524]  D. Mukhopadhyay,et al.  Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.

[525]  S. Hirohashi,et al.  Microsatellite instability in primary and metastatic lung carcinomas , 1995, Genes, chromosomes & cancer.

[526]  S. Lam,et al.  Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. , 1995, Cancer research.

[527]  M. Kelley,et al.  Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. , 1995, Oncogene.

[528]  P. Zimmerman,et al.  Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. , 1995, Cancer research.

[529]  F. Kaye,et al.  CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. , 1995, Oncogene.

[530]  S. Zienolddiny,et al.  A hereditary genetic marker closely associated with microsatellite instability in lung cancer. , 1995, Cancer research.

[531]  M. Shipp,et al.  Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. , 1995, Cancer research.

[532]  J. Minna,et al.  Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. , 1995, Journal of the National Cancer Institute.

[533]  T. Soussi,et al.  Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.

[534]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[535]  J. Gray,et al.  Identification of novel regions of altered DNA copy number in small cell lung tumors , 1995, Genes, chromosomes & cancer.

[536]  R. Whyte,et al.  Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. , 1995, British Journal of Cancer.

[537]  A. Gazdar,et al.  Telomerase activity in small-cell and non-small-cell lung cancers. , 1995, Journal of the National Cancer Institute.

[538]  S. Steinberg,et al.  Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. , 1995, Journal of the National Cancer Institute.

[539]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[540]  J. Whitsett,et al.  Gene Structure and Expression of Human Thyroid Transcription Factor-1 in Respiratory Epithelial Cells (*) , 1995, The Journal of Biological Chemistry.

[541]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[542]  J. Minna,et al.  Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. , 1995, JAMA.

[543]  C. D. Edwards,et al.  Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.

[544]  P. Zimmerman,et al.  Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. , 1995, Cancer research.

[545]  V. Rusch,et al.  p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. , 1994, Chest.

[546]  A. Gazdar,et al.  K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. , 1994, Cancer research.

[547]  A. Okamoto,et al.  Mutations and altered expression of p16INK4 in human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[548]  J. Yokota,et al.  Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. , 1994, Cancer research.

[549]  Y. Nakamura,et al.  Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. , 1994, Cancer research.

[550]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[551]  T. Sellers,et al.  Segregation analysis of smoking-associated malignancies: evidence for Mendelian inheritance. , 1994, American journal of medical genetics.

[552]  K. Kok,et al.  A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. , 1994, Cancer research.

[553]  P. Zimmerman,et al.  Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non‐small cell lung cancer , 1994, Genes, chromosomes & cancer.

[554]  G. Nicolson,et al.  c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. , 1994, Cancer research.

[555]  W. Benedict,et al.  Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. , 1994, Journal of the National Cancer Institute.

[556]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[557]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[558]  W. Kolch,et al.  Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. , 1994, Oncogene.

[559]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[560]  F. Askin,et al.  Frequent loss of chromosome 9 in human primary non-small cell lung cancer. , 1994, Cancer research.

[561]  S. Rodenhuis,et al.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. , 1994, The Journal of clinical investigation.

[562]  D. Shibata,et al.  c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. , 1994, The American journal of pathology.

[563]  Yoshiro,et al.  Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. , 1994, The American journal of pathology.

[564]  H. Katz.  bcl-2 protein in non-small-cell lung carcinoma. , 1994, The New England journal of medicine.

[565]  K. Matsumoto,et al.  Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. , 1993, The Journal of biological chemistry.

[566]  J. Minna,et al.  Human lung cancer cell lines exhibit resistance to retinoic acid treatment. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[567]  P. Carlson,et al.  c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. , 1993, Cancer research.

[568]  J. Mate,et al.  Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.

[569]  J. Yokota,et al.  Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. , 1993, Oncogene.

[570]  J. Minna,et al.  Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. , 1993, American journal of respiratory cell and molecular biology.

[571]  R. Figlin,et al.  Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. , 1993, Oncogene.

[572]  A. Gazdar,et al.  Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. , 1993, Journal of the National Cancer Institute.

[573]  Y. Nakamura,et al.  Deletion mapping of the short arm of chromosome 8 in non‐small cell lung carcinoma , 1993, Genes, chromosomes & cancer.

[574]  E. Dmitrovsky,et al.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. , 1993, Cancer research.

[575]  C. Harris,et al.  Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. , 1993, Cancer research.

[576]  M. Spang‐Thomsen,et al.  Expression of myc family oncoproteins in small‐cell lung‐cancer cell lines and xenografts , 1993, International journal of cancer.

[577]  T. Tsukamoto,et al.  Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. , 1993, Cancer research.

[578]  Johnson Be,et al.  The biology of lung cancer. , 1993, Seminars in oncology.

[579]  Y. Miller,et al.  Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. , 1993, Current problems in cancer.

[580]  R. Ueda,et al.  Frequent homozygous deletions in lung cancer cell lines detected by a DNA marker located at 3p21.3-p22. , 1993, Oncogene.

[581]  T. Nakamura,et al.  Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. , 1993, British Journal of Cancer.

[582]  E. Oldfield,et al.  Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.

[583]  H. Poulsen,et al.  Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. , 1992, Cancer research.

[584]  S. Rodenhuis,et al.  Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.

[585]  H. Antoniades,et al.  Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[586]  R. Ueda,et al.  Three distinct regions involved in 3p deletion in human lung cancer. , 1992, Oncogene.

[587]  S. Baylin,et al.  Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[588]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.

[589]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[590]  S. Rodenhuis,et al.  Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.

[591]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[592]  K. Sugimachi,et al.  Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. , 1990, Cancer research.

[593]  J. Minna,et al.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. , 1990, Oncogene.

[594]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[595]  S. Naylor,et al.  Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. , 1990, Cancer research.

[596]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[597]  P. Nowell,et al.  Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. , 1990, Cancer research.

[598]  M. Noguchi,et al.  Amplification of protooncogenes in surgical specimens of human lung carcinomas. , 1989, Cancer research.

[599]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[600]  J. Roth,et al.  Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. , 1989, Cancer research.

[601]  G. Draper,et al.  Non-ocular cancer in relatives of retinoblastoma patients. , 1989, British Journal of Cancer.

[602]  R. Ueda,et al.  Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. , 1989, Cancer research.

[603]  Knudson Ag.  The ninth Gordon Hamilton-Fairley memorial lecture: Hereditary cancers: clues to mechanisms of carcinogenesis , 1989 .

[604]  K. Münger,et al.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.

[605]  J. Battey,et al.  Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer , 1988, Molecular and cellular biology.

[606]  J. Minna,et al.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. , 1988, Science.

[607]  J. Minna,et al.  Molecular genetics of lung cancer. , 1988, Annual review of medicine.

[608]  J. Osinga,et al.  Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer , 1987, Nature.

[609]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[610]  P. Zimmerman,et al.  PLOIDY AS A PROGNOSTIC DETERMINANT IN SURGICALLY TREATED LUNG CANCER , 1987, The Lancet.

[611]  N. Bleehen,et al.  Oncogene amplification and chromosomal abnormalities in small cell lung cancer , 1987, Journal of cellular biochemistry.

[612]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.

[613]  J. Battey,et al.  Human small-cell lung cancers show amplification and expression of the N-myc gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[614]  R. Elston,et al.  Increased familial risk for lung cancer. , 1986, Journal of the National Cancer Institute.

[615]  J. Battey,et al.  L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer , 1985, Nature.

[616]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[617]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[618]  R. Evans,et al.  Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. , 1984, Science.

[619]  Y H Xu,et al.  Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. , 1984, Science.

[620]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[621]  S. Newsom,et al.  LOCAL CHEMOTHERAPY FOR PSEUDOMONAS LUNG ABSCESS , 1974 .

[622]  A. Lilienfeld,et al.  Familial aggregation of lung cancer among hospital patients. , 1963, Public health reports.

[623]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[624]  L. Tanoue.  Incidence of human papilloma virus in lung cancer , 2011 .

[625]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[626]  Richard Simon,et al.  Gene expression-based prognostic signatures in lung cancer: ready for clinical use? , 2010, Journal of the National Cancer Institute.

[627]  C. Croce,et al.  MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs. , 2010, IDrugs : the investigational drugs journal.

[628]  Paolo Boffetta,et al.  Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. , 2009, Cancer research.

[629]  J. Yokota,et al.  Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. , 2009, Carcinogenesis.

[630]  D. Hayes,et al.  HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. , 2009, The Journal of clinical investigation.

[631]  P. Jänne,et al.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[632]  良一 小野里.  LKB1 gene mutations in Japanese lung cancer patients , 2009 .

[633]  G. Qiao,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .

[634]  Y. Kotake,et al.  pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. , 2007, Genes & development.

[635]  Yeul-Hong Kim,et al.  Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung. , 2007, Lung cancer.

[636]  Nicholas G Martin,et al.  Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. , 2007, Human molecular genetics.

[637]  J. Luketich,et al.  Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. , 2006, Neoplasia.

[638]  G. Watanabe,et al.  Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis. , 2006, Anticancer research.

[639]  J. Rothberg,et al.  Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. , 2005, Cold Spring Harbor symposia on quantitative biology.

[640]  L. Fabbri,et al.  Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[641]  Y. Ishikawa,et al.  High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs , 2005, Journal of Cancer Research and Clinical Oncology.

[642]  Amie Y Lee,et al.  A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. , 2004, Neoplasia.

[643]  N. Agnantis,et al.  Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. , 2004, Histology and histopathology.

[644]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[645]  H. Kato,et al.  Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer , 2003, International journal of cancer.

[646]  F. Oesch,et al.  Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[647]  M. Esteller.  Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. , 2003, Advances in experimental medicine and biology.

[648]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[649]  Yusuke Nakamura,et al.  Identification of semaphorin3B as a direct target of p53. , 2002, Neoplasia.

[650]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[651]  F. Wright,et al.  Global methylation profiling of lung cancer identifies novel methylated genes. , 2001, Neoplasia.

[652]  E. Mark,et al.  p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. , 2001, Cancer research.

[653]  平島 奈緒子.  Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas : A comparative immunohistochemical and fluorescence in situ hybridization study , 2001 .

[654]  A. Gazdar,et al.  Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[655]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[656]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[657]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[658]  R. Figlin,et al.  Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer , 1999, Journal of Cancer Research and Clinical Oncology.

[659]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[660]  G. Swanson,et al.  Increased cancer risk among relatives of nonsmoking lung cancer cases , 1999, Genetic epidemiology.

[661]  C I Amos,et al.  Is there a genetic basis for lung cancer susceptibility? , 1999, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[662]  M. Bibbo,et al.  The role of pRb2/p130 protein in diagnosing lung carcinoma on fine needle aspiration biopsies. , 1999, Pathology, research and practice.

[663]  M. Tschan,et al.  Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. , 1998, Oncogene.

[664]  I. Wistuba,et al.  Molecular Abnormalities in the Sequential Development of Lung Carcinoma , 1998 .

[665]  I. Petersen,et al.  Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p. , 1997, British Journal of Cancer.

[666]  M. Fukuoka,et al.  Differential expressions of cyclin A and the retinoblastoma gene product in histological subtypes of lung cancer cell lines , 1997, Journal of Cancer Research and Clinical Oncology.

[667]  S. Spivack,et al.  The molecular epidemiology of lung cancer. , 1997, Critical reviews in toxicology.

[668]  L. V. van't Veer,et al.  Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[669]  M. Caputi,et al.  Prognostic role of cyclin D1 in non small cell lung cancer: an immunohistochemical analysis. , 1997, European journal of histochemistry : EJH.

[670]  P. Hasleton,et al.  Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. , 1997, British Journal of Cancer.

[671]  Y. Ishikawa,et al.  A follow-up study of progression from dysplasia to squamous cell carcinoma with immunohistochemical examination of p53 protein overexpression in the bronchi of ex-chromate workers. , 1997, British Journal of Cancer.

[672]  M. Oda,et al.  Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. , 1997, British Journal of Cancer.

[673]  Tsung-Teh Wu,et al.  Extracellular matrix expression in metastasizing and nonmetastasizing adenocarcinomas of the lung. , 1997, Human pathology.

[674]  J. Shay,et al.  Telomerase activity in human cancer. , 1996, Current opinion in oncology.

[675]  S. Steinberg,et al.  MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer , 1996, Journal of cellular biochemistry. Supplement.

[676]  E. Sausville,et al.  Bombesin receptor structure and expression in human lung carcinoma cell lines , 1996, Journal of cellular biochemistry. Supplement.

[677]  Philip Smith,et al.  Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. , 1995, Cancer research.

[678]  F. Kaye,et al.  Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. , 1994, Oncogene.

[679]  D. Forman,et al.  Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility. , 1994, British medical bulletin.

[680]  B. Johnson,et al.  The biology of lung cancer. , 1993, Seminars in oncology.

[681]  M. Groudine,et al.  Control of c-myc regulation in normal and neoplastic cells. , 1991, Advances in cancer research.

[682]  G. Del Sal,et al.  Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human tumors , 1989, International journal of cancer.

[683]  J. Yokota,et al.  Multiple genetic alterations in small-cell lung carcinoma. , 1989, Princess Takamatsu symposia.

[684]  M. Matthews.  Pathology of small cell lung cancer , 1985 .

[685]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.

[686]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.